IL294926A - Foxvirus-based vectors produced by natural or artificial DNA and their uses - Google Patents
Foxvirus-based vectors produced by natural or artificial DNA and their usesInfo
- Publication number
- IL294926A IL294926A IL294926A IL29492622A IL294926A IL 294926 A IL294926 A IL 294926A IL 294926 A IL294926 A IL 294926A IL 29492622 A IL29492622 A IL 29492622A IL 294926 A IL294926 A IL 294926A
- Authority
- IL
- Israel
- Prior art keywords
- smva
- fragments
- dna
- sequences
- mva
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
- C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969628P | 2020-02-03 | 2020-02-03 | |
| US202063113803P | 2020-11-13 | 2020-11-13 | |
| PCT/US2021/016247 WO2021158565A2 (en) | 2020-02-03 | 2021-02-02 | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL294926A true IL294926A (en) | 2022-09-01 |
Family
ID=77200801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL294926A IL294926A (en) | 2020-02-03 | 2021-02-02 | Foxvirus-based vectors produced by natural or artificial DNA and their uses |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4100514A4 (enExample) |
| JP (2) | JP2023512294A (enExample) |
| KR (1) | KR20220148823A (enExample) |
| CN (1) | CN115397998A (enExample) |
| AU (2) | AU2021217073A1 (enExample) |
| BR (1) | BR112022014738A2 (enExample) |
| CA (1) | CA3168836A1 (enExample) |
| IL (1) | IL294926A (enExample) |
| MX (1) | MX2022009200A (enExample) |
| WO (1) | WO2021158565A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| BR112023015467A2 (pt) | 2021-02-02 | 2023-10-10 | Geovax Inc | Vetor viral de vaccinia ankara recombinante modificado, métodos para aumentar uma resposta imunológica a um antígeno alvo em um paciente e para prevenir, tratar ou induzir uma resposta imunológica contra um antígeno alvo, e, composição farmacêutica |
| CN115433741A (zh) * | 2022-06-23 | 2022-12-06 | 广西大学 | 盖他病毒为载体表达报告蛋白的重组病毒的构建方法 |
| CN118240879A (zh) * | 2023-11-01 | 2024-06-25 | 上海市重大传染病和生物安全研究院 | 骨架质粒、重组质粒以及猴痘病毒颗粒和应用 |
| CN119506355B (zh) * | 2025-01-15 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 一种用于重组痘病毒包装的载体系统及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3099330A1 (en) * | 2018-05-02 | 2019-11-07 | Tonix Pharma Holdings Limited | Synthetic chimeric vaccinia virus |
-
2021
- 2021-02-02 CN CN202180025623.2A patent/CN115397998A/zh active Pending
- 2021-02-02 EP EP21750239.2A patent/EP4100514A4/en active Pending
- 2021-02-02 BR BR112022014738A patent/BR112022014738A2/pt unknown
- 2021-02-02 AU AU2021217073A patent/AU2021217073A1/en active Pending
- 2021-02-02 KR KR1020227030182A patent/KR20220148823A/ko active Pending
- 2021-02-02 MX MX2022009200A patent/MX2022009200A/es unknown
- 2021-02-02 JP JP2022547055A patent/JP2023512294A/ja active Pending
- 2021-02-02 WO PCT/US2021/016247 patent/WO2021158565A2/en not_active Ceased
- 2021-02-02 CA CA3168836A patent/CA3168836A1/en active Pending
- 2021-02-02 IL IL294926A patent/IL294926A/en unknown
-
2025
- 2025-12-24 AU AU2025287330A patent/AU2025287330A1/en active Pending
-
2026
- 2026-03-04 JP JP2026033811A patent/JP2026094336A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021158565A3 (en) | 2021-09-16 |
| JP2023512294A (ja) | 2023-03-24 |
| EP4100514A2 (en) | 2022-12-14 |
| WO2021158565A2 (en) | 2021-08-12 |
| EP4100514A4 (en) | 2024-06-12 |
| JP2026094336A (ja) | 2026-06-09 |
| CA3168836A1 (en) | 2021-08-12 |
| MX2022009200A (es) | 2023-01-04 |
| BR112022014738A2 (pt) | 2022-10-11 |
| AU2021217073A1 (en) | 2022-08-18 |
| CN115397998A (zh) | 2022-11-25 |
| AU2025287330A1 (en) | 2026-01-22 |
| KR20220148823A (ko) | 2022-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4100514A2 (en) | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof | |
| JP6706656B2 (ja) | Ｕｌ１２８複合体の送達及びｃｍｖ感染の予防のためのｍｖａワクチン | |
| US7338662B2 (en) | Recombinant poxvirus expressing homologous genes inserted into the foxviral genome | |
| CN102341120B (zh) | 结合重复免疫的优化早晚期启动子辅助对复制缺陷型重组病毒疫苗抗原的细胞毒t细胞应答 | |
| US12584146B2 (en) | Synthetic modified vaccinia Ankara (SMVA) based coronavirus vaccines | |
| US20230140549A1 (en) | Expression system for expressing herpesvirus glycoprotein complexes | |
| BR0115533B1 (pt) | Variation of vaccinia ankara modified virus | |
| AU2022205166A1 (en) | Recombinant modified vaccinia virus Ankara (MVA) Foot and mouth disease virus (FMDV) vaccine | |
| US20250215456A1 (en) | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof | |
| Melamed et al. | Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants | |
| TW202413636A (zh) | 嵌合痘病毒 | |
| Gao et al. | Design and construction of a fast synthetic modified vaccinia virus Ankara reverse genetics system for advancing vaccine development | |
| US12029787B2 (en) | Method for generating recombinant poxviruses | |
| Bissa et al. | Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain | |
| WO2026104601A1 (en) | Viral vectors for enhanced immune responses to multimeric protein particle displayed antigens | |
| Hall | Promoter and leader sequence effects on immunological potency of recombinant modified vaccinia virus Ankara delivering tuberculosis antigens | |
| Smith | Vaccinia Virus as a Carrier of Vaccine Antigens | |
| Hagen | Design of a Tetracycline Operon Inducible System for the Control of Vaccinia Virus Replication: Implications for Vaccine Development | |
| HK1076642B (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1170772A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1171249A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1161677B (en) | Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines | |
| HK1144700A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |